-
Ochratoxin A activates opposing c-MET/PI3K/Akt and MAPK/ERK 1-2 pathways in human proximal tubule HK-2 cells.
Archives of toxicology 20150801
-
Proteinase-activated receptor 2 (PAR(2)) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level.
Histochemistry and cell biology 20121201
-
Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates.
The Analyst 20120907
-
Association of activated c-Met with NRAS-mutated human melanomas.
International journal of cancer 20120715
-
Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines.
Pathology oncology research : POR 20120401
-
A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors.
International journal of cancer 20120315
-
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Molecular cancer therapeutics 20120301
-
MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks.
International journal of cancer 20120201
-
c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.
Molecular medicine (Cambridge, Mass.) 20120101
-
Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma.
The American journal of pathology 20111201
-
Comprehensive analysis of kinase inhibitor selectivity.
Nature biotechnology 20111030
-
PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Anti-cancer drugs 20111001
-
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
Journal of medicinal chemistry 20110922
-
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.
British journal of cancer 20110906
-
c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
Hepatology (Baltimore, Md.) 20110902
-
Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110501
-
Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
Journal of the National Cancer Institute 20110420
-
Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 20110201
-
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
Cancer research 20110201
-
HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.
Laboratory investigation; a journal of technical methods and pathology 20110101
-
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 20110101
-
Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
Neoplasia (New York, N.Y.) 20110101
-
Involvement of c-Met- and phosphatidylinositol 3-kinase dependent pathways in arsenite-induced downregulation of catalase in hepatoma cells.
Biological & pharmaceutical bulletin 20110101
-
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Chemistry & biology 20101124
-
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
Cancer research 20101001
-
Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100901
-
Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Molecular cancer therapeutics 20100501
-
Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.
Cancer research 20100215
-
Scatter factor protects tumor cells against apoptosis caused by TRAIL.
Anti-cancer drugs 20100101
-
Efficacy of c-Met inhibitor for advanced prostate cancer.
BMC cancer 20100101
-
N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Bioorganic & medicinal chemistry letters 20091201
-
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
The Journal of pathology 20090701
-
N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Bioorganic & medicinal chemistry letters 20090301
-
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
BMC cancer 20090101
-
Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
Breast cancer research and treatment 20081101
-
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Molecular cancer therapeutics 20081101
-
Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
Head & neck 20080801
-
Hepatocyte growth factor and c-Met promote dendritic maturation during hippocampal neuron differentiation via the Akt pathway.
Cellular signalling 20080501
-
Hepatocyte growth factor promotes migration of human myeloma cells.
Haematologica 20080401
-
An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080401
-
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.
Molecular cancer therapeutics 20080401
-
Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5.
BMC cancer 20080101
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science (New York, N.Y.) 20070518
-
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Cancer research 20070415
-
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.
Cancer research 20070201
-
Inhibition of the met receptor in mesothelioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20051115
-
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Clinical cancer research : an official journal of the American Association for Cancer Research 20050315
-
A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 20041001
-
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Cancer research 20031101
